Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

emergent biosolutions inc. - EBS

EBS

Close Chg Chg %
7.47 -0.31 -4.15%

Closed Market

7.16

-0.31 (4.15%)

Volume: 788.62K

Last Updated:

Jul 25, 2025, 3:59 PM EDT

Trade Now

Company Overview: emergent biosolutions inc. - EBS

EBS Key Data

Open

$7.49

 Day Range

7.10 - 7.49

52 Week Range

4.02 - 15.09

 Market Cap

$405.46M

Shares Outstanding

54.28M

 Public Float

51.92M

Beta

2.09

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.55

Yield

0.00%

 Dividend

$1.86

EX-DIVIDEND DATE

Aug 1, 2016

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.37M

  

EBS Performance

1 Week
 
 3.46%
 
1 Month
 
 12.91%
 
3 Months
 
 30.60%
 
1 Year
 
 -48.68%
 
5 Years
 
 -92.02%
 

EBS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About emergent biosolutions inc. - EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

EBS At a Glance

Emergent BioSolutions, Inc.
300 Professional Drive
Gaithersburg, Maryland 20879
Phone 1-240-631-3200 Revenue 1.04B
Industry Pharmaceuticals: Major Net Income -190,600,000.00
Sector Health Technology Employees 900
Fiscal Year-end 12 / 2025
View SEC Filings

EBS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.486
Price to Book Ratio 1.075
Price to Cash Flow Ratio 8.632
Enterprise Value to EBITDA 20.097
Enterprise Value to Sales 1.032
Total Debt to Enterprise Value 0.628

EBS Efficiency

Revenue/Employee 1,159,555.556
Income Per Employee -211,777.778
Receivables Turnover 6.755
Total Asset Turnover 0.646

EBS Liquidity

Current Ratio 3.687
Quick Ratio 1.767
Cash Ratio 0.65

EBS Profitability

Gross Margin 29.245
Operating Margin -5.596
Pretax Margin -13.693
Net Margin -18.264
Return on Assets -11.795
Return on Equity -33.672
Return on Total Capital -16.447
Return on Invested Capital -16.824

EBS Capital Structure

Total Debt to Total Equity 140.037
Total Debt to Total Capital 58.34
Total Debt to Total Assets 48.40
Long-Term Debt to Equity 139.478
Long-Term Debt to Total Capital 58.107
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Emergent Biosolutions Inc. - EBS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
1.79B 1.12B 1.05B 1.04B
Sales Growth
+15.26% -37.66% -6.10% -0.54%
Cost of Goods Sold (COGS) incl D&A
813.10M 750.40M 756.80M 738.40M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
126.30M 148.90M 129.10M 112.00M
Depreciation
67.80M 89.00M 63.50M 46.90M
Amortization of Intangibles
58.50M 59.90M 65.60M 65.10M
COGS Growth
+47.27% -7.71% +0.85% -2.43%
Gross Income
979.60M 367.10M 292.50M 305.20M
Gross Income Growth
-2.36% -62.53% -20.32% +4.34%
Gross Profit Margin
+54.64% +32.85% +27.88% +29.24%
2021 2022 2023 2024 5-year trend
SG&A Expense
581.50M 526.00M 464.50M 363.60M
Research & Development
234.00M 188.30M 107.80M 64.90M
Other SG&A
347.50M 337.70M 356.70M 298.70M
SGA Growth
+14.29% -9.54% -11.69% -21.72%
Other Operating Expense
- - - -
-
Unusual Expense
45.50M 11.10M 554.40M 50.30M
EBIT after Unusual Expense
352.60M (170.00M) (726.40M) (108.70M)
Non Operating Income/Expense
(9.50M) (11.80M) 92.00M 36.80M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
28.70M 37.20M 96.80M 71.00M
Interest Expense Growth
+4.74% +29.62% +160.22% -26.65%
Gross Interest Expense
28.70M 37.20M 96.80M 71.00M
Interest Capitalized
- - - -
-
Pretax Income
314.40M (219.00M) (731.20M) (142.90M)
Pretax Income Growth
-22.79% -169.66% -233.88% +80.46%
Pretax Margin
+17.54% -19.60% -69.68% -13.69%
Income Tax
83.50M (7.40M) 29.30M 47.70M
Income Tax - Current - Domestic
11.20M (7.50M) (100.00K) 5.80M
Income Tax - Current - Foreign
28.40M 33.80M 36.70M 47.40M
Income Tax - Deferred - Domestic
42.30M (40.90M) (3.20M) (4.40M)
Income Tax - Deferred - Foreign
1.60M 7.20M (4.10M) (1.10M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
230.90M (211.60M) (760.50M) (190.60M)
Minority Interest Expense
- - - -
-
Net Income
230.90M (211.60M) (760.50M) (190.60M)
Net Income Growth
-24.32% -191.64% -259.40% +74.94%
Net Margin Growth
+12.88% -18.94% -72.48% -18.26%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
230.90M (211.60M) (760.50M) (190.60M)
Preferred Dividends
- - - -
-
Net Income Available to Common
230.90M (211.60M) (760.50M) (190.60M)
EPS (Basic)
4.3159 -4.2236 -14.8535 -3.5962
EPS (Basic) Growth
-25.45% -197.86% -251.68% +75.79%
Basic Shares Outstanding
53.50M 50.10M 51.20M 53.00M
EPS (Diluted)
4.268 -4.2236 -14.8535 -3.5962
EPS (Diluted) Growth
-24.74% -198.96% -251.68% +75.79%
Diluted Shares Outstanding
54.10M 50.10M 51.20M 53.00M
EBITDA
524.40M (10.00M) (42.90M) 53.60M
EBITDA Growth
-13.88% -101.91% -329.00% +224.94%
EBITDA Margin
+29.25% -0.89% -4.09% +5.14%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 14.333
Number of Ratings 3 Current Quarters Estimate 0.043
FY Report Date 09 / 2025 Current Year's Estimate 1.03
Last Quarter’s Earnings -0.26 Median PE on CY Estimate N/A
Year Ago Earnings -0.23 Next Fiscal Year Estimate 0.96
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 3 2
Mean Estimate 0.04 0.34 1.03 0.96
High Estimates 0.24 0.52 1.22 3.82
Low Estimate -0.10 0.24 0.75 -1.90
Coefficient of Variance 406.53 47.18 24.04 421.32

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Emergent Biosolutions Inc. - EBS

Date Name Shares Transaction Value
Jul 16, 2025 William Hartzel SVP, Bioservices 103,692 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.36 per share 763,173.12
Mar 11, 2025 Richard Scott Lindahl EVP, Chief Financial Officer 299,225 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Richard Scott Lindahl EVP, Chief Financial Officer 484,490 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Joseph C. Papa President and CEO; Director 282,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Joseph C. Papa President and CEO; Director 1,032,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Paul Anthony Williams SVP, Products Business 86,335 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Paul Anthony Williams SVP, Products Business 210,114 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Coleen Glessner EVP, Quality & Ethics, and CPL 176,656 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Coleen Glessner EVP, Quality & Ethics, and CPL 249,613 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 William Hartzel SVP, Bioservices 214,711 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Jessica Perl SVP, General Counsel, Corp Sec 68,387 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Jessica Perl SVP, General Counsel, Corp Sec 95,945 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Simon Lowry SVP, R&D, CMO 91,982 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Simon Lowry SVP, R&D, CMO 102,999 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Emergent Biosolutions Inc. in the News